

SynAct to host Capital Markets Day in Stockholm June 4

SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, invites investors, analysts and media to a Capital Markets Day in Stockholm on Wednesday, June 4, 2025.

SynAct is progressing with the recruitment of patients to its Phase 2b ADVANCE study in patients with newly diagnosed severe rheumatoid arthritis (RA) and is accelerating its plans to expand the use of resomelagon into other indications. Please join the CMD to hear about SynAct’s efforts and path forward.

The agenda and more detailed information will be announced closer to the event.

When: June 4, 2025, from 15:00-17:00 CEST
Location: Sergelkonferensen
Address: Mäster Samuelsgatan 42, Stockholm
Conference room: Wall Street

Registration for the event is made by mailing investor.relations@synactpharma.com

For further information, please contact:

Jeppe Øvlesen, CEO SynAct Pharma
Tel: +45 2844 7567
Email: JOO@synactpharma.com

About SynAct Pharma AB

SynAct Pharma AB (publ) (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and anti-inflammatory activity in autoimmune and inflammatory diseases to help patients achieve immune balance and overcome their inflammation. For more information: www.synactpharma.com.

Attachments

[SynAct to host Capital Markets Day in Stockholm June 4](#)